1)Hayashi N, Izumi N, Kumada H, et al : Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan : CONCERTO-1, a phase Ⅲ trial. J Hepatol 61:219-227,2014
2)Berzins SP, Ritchie DS : Natural killer T cells: drivers or passengers in preventing human disease? Nat Rev Immunol 14:640-646,2014
3)Kakimi K, Guidotti LG, Koezuka Y, et al : Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192:921-930,2000
4)Ito H, Ando K, Ishikawa T, et al : Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL : activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. Int Immunol 20:869-879,2008
5)Woltman AM, Ter Borg MJ, Binda RS, et al : Alpha-galactosylceramide in chronic hepatitis B infection : results from a randomized placebo-controlled Phase Ⅰ/Ⅱ trial. Antivir Ther 14:809-818,2009
6)Ito H, Ando T, Ando K, et al : Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity. Immunology 142:614-623,2014